tbuckley/cabot-search huggingface dataset:
Malignant lymphoma detected by screening program with esophagogastroduodenoscopy of one private screening center in Japan
Authors: T. Nakamura, M. Ikeda, S. Shibata, Y. Kon, K. Konuma, T. Sanada, H. Gonda, Y. Suto, K. Kobayashi, H. Tamura, M. Kobayashi, A. Hasegawa, Y. Amagasa, A. Suzuki, M. Fukuda, C. Aoyagi, N. Matsuura, Y. Kawashima, M. Shimura, N. Takita
Journal: Annals of Oncology (2018)
MA12.07 gC1qR Expression is Independently Prognostic for Survival Benefit Following Chemotherapy in Mesothelioma
Authors: X. Li, T. Eguchi, R. Aly, N. Chintala, K.S. Tan, J. Messinger, M. Zauderer, B. Ghebrehiwet, P. Adusumilli, E. Peerschke
Journal: Journal of Thoracic Oncology (2018)
MA18.03 How in the Real World Are Lung Cancer Patients Treated? The Ontario, Canada Experience
Authors: W. Evans, W. Flanagan, C. Gauvreau, P. Manivong, S. Memon, N. Fitzgerald, J. Goffin, R. Garner, E. Khoo, N. Mittmann
Journal: Journal of Thoracic Oncology (2018)
Nivolumab and ipilimumab in combination with radiotherapy in patients with locally advanced head and neck cancer
Authors: J.M. Johnson, V. Bar Ad, E. Lorber, A. Luginbuhl, J.M. Curry, D. Cognetti, S. Keith, R. Axelrod, R. Zinner, U. Rodeck, L.A. Harshyne, A. Argiris
Journal: Annals of Oncology (2018)
Distant disease-free survival (DDFS) according to response category in neoadjuvant endocrine therapy (NET): 6-year analysis in phase III NEOS trial
Authors: H. Iwata, N. Masuda, Y. Yamamoto, T. Fujisawa, T. Toyama, N. Taira, M. Kashiwaba, S. Ohtani, T. Sakai, Y. Hasegawa, R. Nakamura, H. Akabane, Y. Shibahara, H. Sasano, T. Yamaguchi, Y. Ohashi
Journal: Annals of Oncology (2018)
Effect of oral magnesium supplementation on the kinetics of magnesium wasting induced by EGFR targeted antibody therapy for colorectal carcinoma (MAGNET trial)
Authors: H. Piessevaux, W. Demey, A. Bols, J. Janssens, M. Polus, H. Rezaei Kalantari, S. Laurent, A. Demols, Y. Humblet, G. Deboever, K. Kargar Samani, M. Ferrante, E. Monsaert, T. Rondou, J.-L. van Laethem, S. Tejpar
Journal: Annals of Oncology (2018)
P3.13-22 Real World Study of Afatinib in First-Line or Re-Challenge Setting for Patients with EGFR Mutant Non-Small Cell Lung Cancer.
Authors: H. Tanaka, K. Taima, M. Itoga, Y. Ishioka, K. Baba, T. Shiratori, Y. Tanaka, H. Nakagawa, T. Morimoto, Y. Hasegawa, H. Yasugahira, K. Okudera, S. Takanashi, S. Tasaka
Journal: Journal of Thoracic Oncology (2018)
MA14.02 Use and Impact of A Systematic Advanced Care Planning in Hospitalized Lung Cancer Patients: A Prospective Study
Authors: A.C. Toffart, N. Denis, M. Giaj Levra, L. Sakhri, M. Duruisseaux, J. Pinsolle, L. Ferrer, D. Moro-Sibilot, J. Timsit
Journal: Journal of Thoracic Oncology (2018)
MA01.02 Histologic Subtyping in Pathologic Stage I Lung Adenocarcinoma Provides Risk-Based Stratification for Surveillance
Authors: Y. Takahashi, T. Eguchi, K. Kameda, S. Lu, R. Vaghjiani, K.S. Tan, D. Jones, W. Travis, P. Adusumilli
Journal: Journal of Thoracic Oncology (2018)
P2.13-37 Chloroquine overcomes acquired resistance to icotinib in vitro and in vivo through STAT3/STMN1 pathway
Authors: X. Lyu, L. Zeng, J. Yuan, X. Meng, R. Sun, B. Liu, Y. Bai, X. Liu, Z. Li, S. Yang
Journal: Journal of Thoracic Oncology (2018)
P1.15-21 Creating an Optimal Care Coordination Model to Improve Multidisciplinary Care for Lung Cancer Patients on Medicaid
Authors: A. Marbaugh, T. Asfeldt, R. Oyer, C. Lathan, M. Smeltzer, V. Nolan, M. Ray, N. Faris, M. Nalan, W. Stevens, A. Kramar, L. Lucas, R. Osarogiagbon
Journal: Journal of Thoracic Oncology (2018)
Molecular screening in advanced cancer patients with head and neck cancers: A retrospective analysis of the MOSCATO-01 trial
Authors: A. Houessinon, L. Verlingue, A. Hollebecque, C. Even, L. Lacroix, S. Postel-Vinay, A. Varga, Y. El Dakdouki, R. Balheda, J.-M. Michot, A. Gazzah, A. Marabelle, S. Michiels, E. Rouleau, I. Breuskin, T. de Baere, E. Angevin, J.-Y. Scoazec, J.-C. Soria, C. Massard
Journal: Annals of Oncology (2018)
P1.16-36 Real-Time Ct Guided Video Assisted Thoracoscopic Partial Resection of Peripheral Small-Sized Lung Tumors
Authors: T. Kaiho, H. Suzuki, K. Ohashi, Y. Shiina, Y. Sata, T. Toyoda, A. Hata, T. Yamamoto, J. Morimoto, Y. Sakairi, H. Wada, T. Nakajima, I. Yoshino
Journal: Journal of Thoracic Oncology (2018)
MA19.01 Efficacy and Genomic Correlates of Response to Anti-PD1/PD-L1 Blockade in Non-Small Cell Lung Cancers Harboring Targetable Oncogenes
Authors: N. Vokes, E. Jimenez Alguilar, A. Adeni, R. Umeton, L. Sholl, H. Rizvi, M. Hellmann, M. Awad, E. Van Allen
Journal: Journal of Thoracic Oncology (2018)
MA22.06 Preinvasive Multifocal Neuroendocrine Lesions with Primary Typical Carcinoid Lung Tumors: A Negative Prognostic Factor?
Authors: N. Daddi, V. Tassi, E. Scarnecchia, F. Allison, J. Vannucci, R. Capozzi, V. Liparulo, K. Yasufuku, M. De Perrot, A. Pierre, Ö. Mete, R. Colella, S. Ascani, P. Ferolla, G. Darling, S. Keshavjee, F. Puma, T.K. Waddell
Journal: Journal of Thoracic Oncology (2018)
Maintenance immunotherapy (MI) in recurrent or metastatic squamous cell carcinoma of the head and neck (RMHN)
Authors: Francesco Recchia, Giampiero Candeloro, Stefano Necozione, Massimo Bratta, Roberta Bisegna, Mario Di Staso, Vincenzo Tombolini, Silvio Rea
Journal: Cancer Research (2008)

2153  Background: Patients with RMHN, have been reported to have a wide variety of functional abnormalities of the immune system such as limphocytopenia, severe circulating natural killer (NK) cell deficiency and increased expression of vascular endothelial growth factor (VEGF). The use of new compounds such as taxanes and cetuximab have not extended overall survival (OS) beyond 12 months. We have previously shown that low dose interleukin-2 (IL-2) and 13-cis- retinoic acid (RA) restored the immune function of advanced cancer patients that had a clinical benefit (CB) (partial or complete response , stable disease ), from chemotherapy (Clin Cancer Res 2001;7:1251). A prospective phase II study of MI was conducted in patients with RMHN, not amenable to salvage surgical resection, that had had a CB to an induction chemotherapy with docetaxel (D), ifosfamide (IF) and cisplatin (CDDP) (DIP). Purpose of the study was to evaluate if a MI , through an improvement of the immune function, could increase response duration and OS. Methods: Patients with RMHN received D 60 mg /m2 on day 1, IF 1200 mg/m2 with uromitexan and CDDP 20 mg/m2 on days 1 to 4, every 4 weeks up to six courses. MI, given to patients with a CB, consisted of low-dose IL-2 (1.8 X 106 IU) and oral RA (0.5 mg/Kg) for 5 days/week for 2 cycles of 3 weeks, with a 1-week rest, with intermittent schedules, until progression. The primary end-point was response rate and its duration; secondary end-points were OS, toxicity and the variation of lymphocyte (LY), NK and serum VEGF. Results: From 08/02 to 08/06, 54 patients were enrolled: 51 were males and 3 females; median age was 64 yrs (29-79 yrs). Primitive sites of disease were: larynx 20 patients (37%), pharynx 11 patients (20%), oral cavity 16 patients (30%), paranasal sinuses 2 patients (4%), salivary glands 5 patients (9%). After a median follow-up of 22 months, 263 courses of chemotherapy were administered. The overall response rate was 59% (30 of 54 patients). 48 patients (89%) had a CB and received 211 courses of MI. Median response duration and OS were 10.9 and 21.8 months, respectively. Five patients with a partial response (persistence of neck nodes) were converted to a complete response after 6 months of MI. With respect to baseline values, a statistically significant increase of LY, NK and decrease of VEGF were observed only in patients treated with MI. Toxicity of chemotherapy was moderate, with grade 3 and 4 neutropenia in 12 and 9 patients, respectively, grade 3 gastrointestinal toxicity in 4 patients. Toxicity of MI included grade 2 erythrodermia and grade 2 autoimmune reactions in 10 and 8 patients, respectively. Conclusions: The outpatient administration of DIP, followed by MI was generally well tolerated and showed a promising activity in RMHN. LY, NK and VEGF can be considered as reliable biomarkers for response and survival.
The efficacy and safety of (neo)adjuvant therapy for gastric cancer: A network meta-analysis
Authors: T. van den Ende, E. Ter Veer, M. Machiels, R.M.A. Mali, F.A. Abe Nijenhuis, L.D. Waal, M. Laarman, S.S. Gisbertz, M.C.C.M. Hulshof, M.G.H. van Oijen, H.W.M. van Laarhoven
Journal: Annals of Oncology (2018)
P1.01-48 Nab-Paclitaxel Plus Gemcitabine in Advanced NSCLC After Platinum-Based Chemotherapy: Final Results and Caveolin-1 Expression
Authors: T. Kiriu, M. Tachihara, A. Hata, Y. Hatakeyama, T. Nagano, M. Yamamoto, K. Kobayashi, H. Ohnishi, N. Katakami, Y. Nishimura
Journal: Journal of Thoracic Oncology (2018)
JCSE01.17 Weekly Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy for IIIA-N2 Lung Squamous Cell Carcinoma: A Prospective Phase II Study
Authors: Y. Zhang, J.Q. Zhu, D. Yue, X. Zhao, Q. Zhang, H. Chen, C. Wang
Journal: Journal of Thoracic Oncology (2018)
Integration of oncology and palliative care
Authors: S. Kaasa, J.H. Loge, T. Albreht, E. Bruera, A.T. Caraceni, A. Cervantes, I.J. Higginson, K. Jordan, P. Sjøgren, P. Stone, C. Zimmermann, T. Lundeby
Journal: Annals of Oncology (2018)
MA22.03 SCLC Circulating Tumour Cell Derived Explants: The Clinical Characteristics of Patients Whose Samples Generate CDX
Authors: A. Vickers, L. Carter, M. Galvin, M. Carter, L. Franklin, K. Morris, J. Pierce, K. Frese, F. Blackhall, C. Dive
Journal: Journal of Thoracic Oncology (2018)
Update: Influenza Activity — United States and Worldwide, May 20–October 13, 2018
Authors: Eric J. Chow, C. Todd Davis, Anwar Isa Abd Elal, Noreen Alabi, Eduardo Azziz-Baumgartner, John Barnes, Lenee Blanton, Lynnette Brammer, Alicia P. Budd, Erin Burns, William W. Davis, Vivien G. Dugan, Alicia M. Fry, Rebecca Garten, Lisa A. Grohskopf, Larisa Gubareva, Yunho Jang, Joyce Jones, Krista Kniss, Stephen Lindstrom, Desiree Mustaquim, Rachael Porter, Melissa Rolfes, Wendy Sessions, Calli Taylor, David E. Wentworth, Xiyan Xu, Natosha Zanders, Jacqueline Katz, Daniel Jernigan
Journal: MMWR Morbidity and Mortality Weekly Report (2018)

During May 20-October 13, 2018,* low levels of influenza activity were reported in the United States, with a mix of influenza A and B viruses circulating. Seasonal influenza activity in the Southern Hemisphere was low overall, with influenza A(H1N1)pdm09 predominating in many regions. Antigenic testing of available influenza A and B viruses indicated that no significant antigenic drift in circulating viruses had emerged. In late September, the components for the 2019 Southern Hemisphere influenza vaccine were selected and included an incremental update to the A(H3N2) vaccine virus used in egg-based vaccine manufacturing; no change was recommended for the A(H3N2) component of cell-manufactured or recombinant influenza vaccines. Annual influenza vaccination is the best method for preventing influenza illness and its complications, and all persons aged ≥6 months who do not have contraindications should receive influenza vaccine, preferably before the onset of influenza circulation in their community, which often begins in October and peaks during December-February. Health care providers should offer vaccination by the end of October and should continue to recommend and administer influenza vaccine to previously unvaccinated patients throughout the 2018-19 influenza season (1). In addition, during May 20-October 13, a small number of nonhuman influenza "variant" virus infections† were reported in the United States; most were associated with exposure to swine. Although limited human-to-human transmission might have occurred in one instance, no ongoing community transmission was identified. Vulnerable populations, especially young children and other persons at high risk for serious influenza complications, should avoid swine barns at agricultural fairs, or close contact with swine.§.
P3.04-13 PD-L1-Gene Expression by nCounter Correlates with PD-L1 Protein Expression in Advanced Non-Small Cell Lung Cancer (NSCLC)
Authors: C. Cabrera, C. Aguado, C. Teixidó, L. Pare, J. Castellvi, L. López, E. Marin, X. Bernal, D. Martinez, A. Giménez-Capitán, N. Vinolas, Z. Yeste, N. Baixeras, R. Roman, M. Molina-Vila, N. Reguart
Journal: Journal of Thoracic Oncology (2018)
P2.01-99 Can NGS NSCLC Testing Be Implemented Without in House Expertise? Clinical Utility of the First FDA-Approved Lung Cancer NGS End-To-End Solution
Authors: S. Mcdonough, A. Aiyer, A.M. Velasco Roth, J. Menezes, A. Vora, J. Schulz, J. Degrandpre, E. Mina, J. Shaw
Journal: Journal of Thoracic Oncology (2018)
P2.01-31 Updated EGFR Mutation Frequency in 1,689 NSCLC Brazilian Patients – A National-Wide Study
Authors: C.G. Ferreira, M. Zalis, M. Zukin, G. Castro, C. Mathias, C. Haddad, V.C.D. Lima, L.H. Araujo, C. Baldotto, A. Gelatti, C. Bustamante, M. Custodio, G. Montenegro, A. Souza, M. Reis
Journal: Journal of Thoracic Oncology (2018)
Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again
Authors: Samantha L. Bucktrout, Jeffrey A. Bluestone, Fred Ramsdell
Journal: Genome Medicine (2018)

For at least 300 years the immune system has been targeted to improve human health. Decades of work advancing immunotherapies against infection and autoimmunity paved the way for the current explosion in cancer immunotherapies. Pathways targeted for therapeutic intervention in autoimmune diseases can be modulated in the opposite sense in malignancy and infectious disease. We discuss the basic principles of the immune response, how these are co-opted in chronic infection and malignancy, and how these can be harnessed to treat disease. T cells are at the center of immunotherapy. We consider the complexity of T cell functional subsets, differentiation states, and extrinsic and intrinsic influences in the design, success, and lessons from immunotherapies. The integral role of checkpoints in the immune response is highlighted by the rapid advances in FDA approvals and the use of therapeutics that target the CTLA-4 and PD-1/PD-L1 pathways. We discuss the distinct and overlapping mechanisms of CTLA-4 and PD-1 and how these can be translated to combination immunotherapy treatments. Finally, we discuss how the successes and challenges in cancer immunotherapies, such as the collateral damage of immune-related adverse events following checkpoint inhibition, are informing treatment of autoimmunity, infection, and malignancy.
Abstract 17219: Increased Aortic Stiffness Following Intrauterine Exposure to Chronic Hypoxia in Rats
Authors: Praveen Kumar, Jude Morton, Sandra T Davidge, Po-Yin Cheung, Lisa K Hornberger
Journal: Circulation (2015)

Background: We have previously demonstrated in rats that fetal hypoxia is associated with altered left ventricular (LV) diastolic function beginning in early postnatal life (2 weeks). In the present study we hypothesized that intrauterine hypoxia exposure alters aortic stiffness which may contribute to the evolution of myocardial dysfunction after birth. Methods: Six pregnant rats were exposed to hypoxic conditions (11.5% FiO2) from E15-21and 3 were maintained in normoxic conditions. After delivery, 4 neonatal rats from each group were examined longitudinally at day 1, 3, and week 1, 2, 4, 8 for changes in aortic stiffness. Pups were anesthetized by face mask with 1.5% isoflurane. Aortic stiffness was assessed by measuring the pulse wave velocity (PWV) in the ascending aorta at 3 points: 1. Proximal to the branch of the first brachiocephalic artery 2. At the level of the diaphragm and 3. Just above the aortic bifurcation into the iliac arteries. T1 was the time interval from the peak of the R wave by ECG to onset of flow in the ascending aorta and T2 from peak of the R wave to onset of flow in either the mid aorta or distal aorta. The distance from the suprasternal notch to the subxiphoid process and to the anterior superior iliac spine was measured in each animal. The PWV was calculated using the following equation: [distance/(T2-T1)]. Three consecutive tracings were assessed and the PWV averaged for each study. Statistical analysis was performed using a 2-way ANOVA. Results: In pups exposed to fetal hypoxia, PWV was significantly increased (p≤0.001) compared to controls at day 1 (4.8±1.5 vs. 2.3±0.2 m/s), day 3 (5.5±0.3 vs. 2.6±0.1 m/s) and week 1 (4.4±0.4 vs. 2.8±0.1 m/s). Interestingly, there was an interaction of time and fetal exposure (p=0.006) whereby PWV values converged from weeks 2 - 8 such that fetal exposure to hypoxia no longer had an effect. No correlation was found between LV diastolic function parameters and aortic PWV in the fetal hypoxia rats at any postnatal age. Conclusion: Prenatal exposure to hypoxia was associated with increased aortic stiffness during early development. The lack of a relationship between LV diastolic function and aortic stiffness could suggest these represent independent effects of fetal hypoxia exposure.
Programmed death-ligand 1 (PD-L1) expression and HPV-associated p16 in oropharyngeal squamous cell carcinoma (OSCC) treated with primary curative radiotherapy (RT)
Authors: T. Steiniche, J.G. Eriksen, J.K. Lilja-Fischer, J. Georgsen, P.-T. Vo, M. Busch-Sørensen, D.R. Chirovsky, J. Cheng, D. Aurora-Garg, R. Swaby, J. Overgaard
Journal: Annals of Oncology (2018)
P3.01-34 Short Hydration Regimen with a Modified Dose of Magnesium Supplementation for Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy
Authors: T. Hase, M. Miyazaki, K. Ichikawa, N. Yogo, N. Ozawa, M. Ando, M. Morise, M. Sato, M. Kondo, K. Yamada, Y. Hasegawa
Journal: Journal of Thoracic Oncology (2018)
Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC)
Authors: R.K. Kelley, A.B. El-Khoueiry, T. Meyer, L. Rimassa, P. Merle, S.L. Chan, A. Tran, F. Parnis, V.C. Tam, S. Cattan, D.W. Markby, D.O. Clary, A.-L. Cheng, G.K. Abou-Alfa
Journal: Annals of Oncology (2018)
A phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: Updated analysis of full cervical expansion cohort
Authors: N. Concin, I.B. Vergote, U.N. Lassen, Y. Drew, J.-P. Machiels, H.-T. Arkenau, M.D. Forster, R. Jones, M.L. Johnson, B.M. Slomovitz, J. Spicer, N. Cornez, C. Gennigens, R.L. Coleman, K. Windfeld, S. Ghatta, R.A. Rangwala, D.S. Hong
Journal: Annals of Oncology (2018)
Metal‐Organic Framework Encapsulation Preserves the Bioactivity of Protein Therapeutics
Authors: Congzhou Wang, Gail Sudlow, Zheyu Wang, Sisi Cao, Qisheng Jiang, Alicia Neiner, Jeremiah J. Morrissey, Evan D. Kharasch, Samuel Achilefu, Srikanth Singamaneni
Journal: Advanced Healthcare Materials (2018)

Protein therapeutics are prone to lose their structure and bioactivity under various environmental stressors. This study reports a facile approach using a nanoporous material, zeolitic imidazolate framework-8 (ZIF-8), as an encapsulant for preserving the prototypic protein therapeutic, insulin, against different harsh conditions that may be encountered during storage, formulation, and transport, including elevated temperatures, mechanical agitation, and organic solvent. Both immunoassay and spectroscopy analyses demonstrate the preserved chemical stability and structural integrity of insulin offered by the ZIF-8 encapsulation. Biological activity of ZIF-8-preserved insulin after storage under accelerated degradation conditions (i.e., 40 °C) is evaluated in vivo using a diabetic mouse model, and shows comparable bioactivity to refrigeration-stored insulin (-20 °C). It is also demonstrated that ZIF-8-preserved insulin has low cytotoxicity in vitro and does not cause side effects in vivo. Furthermore, ZIF-8 residue can be completely removed by a simple purification step before insulin administration. This biopreservation approach is potentially applicable to diverse protein therapeutics, thus extending the benefits of advanced biologics to resource-limited settings and underserved populations/regions.
Organophosphate exposures during pregnancy and child neurodevelopment: Recommendations for essential policy reforms
Authors: Irva Hertz-Picciotto, Jennifer B. Sass, Stephanie Engel, Deborah H. Bennett, Asa Bradman, Brenda Eskenazi, Bruce Lanphear, Robin Whyatt
Journal: PLoS Medicine (2018)

In a Policy Forum, Irva Hertz-Picciotto and colleagues review the scientific evidence linking organophosphate pesticides to cognitive, behavioral, and neurological deficits in children and recommend actions to reduce exposures.
Preoperative pembrolizumab (Pembro) with radiation therapy (RT) in patients with operable triple-negative breast cancer (TNBC)
Authors: H.L. McArthur, R. Basho, S. Shiao, D. Park, C. Dang, S. Karlan, S. Knott, M. Mita, C. Dilauro Abaya, A.E. Giuliano, F. Dadmanesh, A. Ho
Journal: Annals of Oncology (2018)
One-Year Outcomes After MitraClip for Functional Mitral Regurgitation
Authors: Gorav Ailawadi, D. Scott Lim, Michael J. Mack, Alfredo Trento, Saibal Kar, Paul A. Grayburn, Donald D. Glower, Andrew Wang, Elyse Foster, Atif Qasim, Neil J. Weissman, Jeffrey Ellis, Lori Crosson, Frank Fan, Irving L. Kron, Paul J. Pearson, Ted Feldman
Journal: Circulation (2018)

Background: Secondary mitral regurgitation (SMR) occurs in the absence of organic mitral valve disease and may develop as the left ventricle dilates or remodels or as a result of leaflet tethering with impaired coaptation, most commonly from apical and lateral distraction of the subvalvular apparatus, with late annular dilatation. The optimal therapy for SMR is unclear. This study sought to evaluate the 1-year adjudicated outcomes of all patients with SMR undergoing the MitraClip procedure in the EVEREST II (Endovascular Valve Edge-to-Edge Repair Study) Investigational Device Exemption program, which is comprised of the randomized clinical trial, the prospective High-Risk Registry, and the REALISM Continued Access Registry (Multicenter Study of the MitraClip System). Methods: Patients with 3+/4+ SMR enrolled in EVEREST II were stratified by non-high surgical risk (non-HR) and high surgical risk (HR) status (defined as Society of Thoracic Surgeons risk of mortality ≥12% or predefined risk factors). Clinical, echocardiographic, and functional outcomes at 1 year were evaluated. Results: A total of 616 patients (482 HR, 134 non-HR; mean age, 73.3±10.5 years; Society of Thoracic Surgeons risk, 10.2±6.9%) with SMR underwent the MitraClip procedure. At baseline, 80.5% of patients were in New York Heart Association class III/IV. Major adverse events at 30 days included death (3.6%), stroke (2.3%), and renal failure (1.5%). At discharge, 88.8% had MR ≤2+. At 1 year, there were 139 deaths, and the Kaplan-Meier estimate of freedom from mortality was 76.8%. The majority of surviving patients (84.7%) remained with MR ≤2+ and New York Heart Association class I/II (83.0%). Kaplan-Meier survival at 1 year was 74.1% in HR patients and 86.4% in non-HR patients ( P =0.0175). At 1 year, both groups achieved comparable MR reduction (MR ≤2+, 84.0% versus 87.0%) and improvement in left ventricular end-diastolic volume (−8.0 mL versus −12.7 mL), whereas New York Heart Association class I/II was found in 80.1% versus 91.8% ( P =0.008) of HR and non-HR patients, respectively. In HR patients, the annualized rate of heart failure hospitalizations decreased from 0.68 to 0.46 in the 12 months before to 12 months after the procedure ( P &lt;0.0001). Conclusions: Transcatheter mitral valve repair with the MitraClip in patients with secondary MR is associated with acceptable safety, reduction of MR severity, symptom improvement, and positive ventricular remodeling. Clinical Trial Registration: https://www.clinicaltrials.gov . Unique identifiers: NCT00209274, NCT01940120, and NCT01931956.
Tolerance of MRSA ST239-TW to chlorhexidine-based decolonization: Evidence for keratinocyte invasion as a mechanism of biocide evasion
Authors: Helene Marbach, Gema Vizcay-Barrena, Kaveh Memarzadeh, Jonathan A. Otter, Smriti Pathak, Robert P. Allaker, Richard D. Harvey, Jonathan D. Edgeworth
Journal: Journal of Infection (2018)